Ashley Gallagher, Associate Editor

The drug also receives orphan drug designation for the treatment of pancreatic neuroendocrine tumors and a Prescription Drug User Fee Act target action date of April 3, 2025.

Customers report that their communication is strong with their pharmacists, but only 51% said their pharmacist was trustworthy.

In the first half of 2024, the FDA approved 23 novel drugs for conditions including alopecia areata, Alzheimer disease, small cell lung cancer, bladder cancer, and more.

This is the first and only on-demand, virus-inactivated, human plasma-derived concentration option that is indicated for this approval.

The drug previously received breakthrough therapy designation for newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia that is in chronic phase.

The system is an outpatient procedure that resurfaces the mucosal lining, making it easier for the body to maintain healthy metabolism and blood glucose levels.

The designation is based on animal model studies that have demonstrated superior efficacy in comparison to sildenafil.

If approved, the drug would be the first in a new class of medications to treat acute pain in over 20 years.

The approval marks the first oral immunotherapy treatment to mitigate allergic reactions, including anaphylaxis.

Paliperidone palmitate (Erzofi; Luye Pharma Group) is approved as a monotherapy for schizophrenia and as an adjunct for schizoaffective disorder.

The similarities were shown for both the US formulation and the EU formulation.

Benzgalantamine (Zunveyl; Alpha Cognition) is a cholinesterase inhibitor indicated for the treatment of mild-to-moderate dementia in adults.

The investigational drug achieved non-inferiority compared to routine Factor VIII.

Patients without insurance may not be able to afford the biosimilar adalimumab-adbm, even if it is available at a more affordable price than its reference product.

In April 2017, the drug was approved to treat the slow loss of the ability to walk for symptomatic patients aged 3 and older who had Batten disease.

A 5:2 intermittent fasting plan combined with meal replacement had better positive outcomes compared with metformin and empagliflozin.

In the session at the 2024 American Association of Colleges of Pharmacy Annual Meeting, presenters highlighted the importance of fostering inclusion for LGBTQ students.

Educators should prioritize integrating social determinants of health (SDOH) for the next generation of pharmacists.

Students express interest in whole-person care and identify it as a gap in their education.

Investigators found that the risk of long COVID decreased over the course of the pandemic.

Currently, limited data show the effect of adverse drug events in the outpatient setting.

In a meta-analysis, high-dose eicosatetraenoic acid and docosahexaenoic acid had the highest efficacy and lowest dropout rate among pharmacological interventions for migraine.

Switching from aflibercept (Eylea; Regeneron Pharmaceuticals) to biosimilar ranibizumab (Lucentis; Genentech) for neovascular age-related macular degeneration could be more cost effective for patients.

After failure with methotrexate, treatment with leflunomide is typically recommended, but treatment with biosimilars could have greater quality-adjusted life years.

The FDA has issued a statement on suicidal thoughts or actions and has launched evaluations for that signal as well as alopecia and aspiration.

Roflumilast is approved as a once daily and steroid-free cream for rapid disease clearance and significant reduction in itch and for long-term disease control.

When initiated at a 15 mg dose and escalated to 30 mg, upadacitinib showed superiority compared with dupilumab, achieving Eczema Area and Severity Score (EASI) 90 at week 16.

ADI-270 is a gamma delta CAR T-cell therapy candidate targeting CD70-positive cancers.

In the 2 mg bulevirtide (Gilead Sciences) group, 44% of individuals achieved HDV RNA that was undetectable compared with 70% in the 10 mg group.

Investigators found improvements over the placebo in metabolic dysfunction-associated steatohepatitis without worsening fibrosis across 3 dosing groups.